20 hrs ago
Merck & Co. Sets New 12-Month High at $58.23
Merck & Co. shares hit a new 52-week high during trading on Tuesday , AnalystRatings.NET reports.
Trending on the Topix Network
Drug Companies Give Million-Dollar Boost to Lobbying
Five pharmaceutical companies have reported million-dollar increases in their spending on lobbying the federal government during the first quarter of 2014.
Thu Apr 17, 2014
Drug Roundup - " April 17, 2014
There have been several noteworthy developments in the drug space recently, which will likely have a material impact on the companies in this sector and the markets they serve.
FDA OKs Merck & Co., Inc. Tablet To Reduce Ragweed Allergies
FDA Approves Merck's RAGWITEKa Sublingual Tablet as Immunotherapy to Treat Short Ragweed Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Adults RAGWITEK is the First and Only FDA Approved Sublingual Allergen Immunotherapy Tablet Indicated for the Treatment of Short Ragweed Pollen Allergies WHITEHOUSE STATION, N.J.-- --Merck , ... (more)
FDA OKs Merck Tablet to Reduce Ragweed Allergies
U.S. regulators have again approved a Merck & Co. tablet for gradually reducing seasonal allergies, this time for ragweed pollen.
Wed Apr 16, 2014
Clinipace becomes a 'preferred provider,' starts acting like a big CRO
By reaching a preferred provider deal with a mid-market drug developer, Clinipace is starting to act like a much bigger contract research organization.
Tue Apr 15, 2014
FDA OKs Merck tablet to reduce grass allergies
Merck & Co. says the Food and Drug Administration has approved its new tablet for grass allergies, Grastek, for patients five to 65 years old.
FDA Approves Merck & Co., Inc.'s Grass Pollen Pill GRASTEK
FDA Approves Merck's GRASTEKA Sublingual Tablet as Immunotherapy to Treat Grass Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Children and Adults WHITEHOUSE STATION, N.J.-- --Merck , known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved GRASTEKA Tablet for ... (more)
Mon Apr 14, 2014
Merck & Co. Given New $61.00 Price Target at Jefferies Group
Jefferies Group's price target would indicate a potential upside of 9.08% from the stock's previous close.
Fri Apr 11, 2014
Merck & Co., Inc.??'s Investigational Chronic Hepatitis C Combination ...
Merck , known as MSD outside of the United States and Canada, today announced interim results from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of an all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus NS3/4A protease inhibitor, and MK-8742, an investigational HCV ... (more)
Thu Apr 10, 2014
Merck & Co. Target of Unusually High Options Trading
Merck & Co. was the target of some unusual options trading activity on Thursday.
Merck's Hepatitis C Drug May Boost Stock
Early Thursday, Merck & Co. announced that a pair of its hepatitis C treatments -- MK-5172 and MK-8742 -- cured 98% of newly treated patients in a midstage clinical trial presented at the European Association for the Study of the Liver in London.
Gilead Sciences: How Big a Threat is Merck?
For those wondering if Merck's hepatitis C drug would prove effective, the answer was a resounding yes.
Wed Apr 09, 2014
BlackBerry CEO May Consider Exiting Handset Business; Celgene...
Shares of Merck & Co. closed up 3.74% on Wednesday with about 16 million shares traded.
Trialnetworks Wins Disruptive Technology And Innovator Of The Year...
April 8, 2014 - TrialNetworks and its Clinical Trial Optimization System won the Disruptive Innovator and Technology of the Year award from Partnerships in Clinical Trials 2014.
Stocks Soar After Fed Minutes; Dow Jumps 181 Points
"The bounce that started yesterday continued in a big way today," noted Schaeffer's Senior Technical Strategist Ryan Detrick, CMT.
Dow Movers: T, MRK
In early trading on Wednesday, shares of Merck & Co. topped the list of the day's best performing Dow Jones Industrial Average components, trading up 1.6%.
Emirates News Agency
MSD and Julphar team up to address patients' needs in the region
WAM DUBAI, 9th April, 2014 -- MSD, the global healthcare company known as Merck and Co within the US, and Julphar, a U.A.E.-based pharmaceutical company, today signed a landmark five-year licensing agreement.
Tue Apr 08, 2014
The Jersey Journal
Frontrunner emerges in bid for Merck's OTC health unit
In the battle between global consumer-health companies for a multibillion dollar foot-care, allergy and sun-tan lotion business, Reckitt Benckiser Group has advantages that rivals will be hard pressed to match.
Mon Apr 07, 2014
This Biotech Market Could Quadruple -- 3 Stocks To Profit
In some respects, this is a golden age for pharmaceuticals. Thousands of medical researchers are making major clinical progress in the fight to treat cancer, heart disease and other afflications.